Foundayo Tablet, Film Coated
Product Images NDC 0002-4839

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Foundayo (NDC 0002-4839). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Fou Uspi Chem V1)

Chemical structure of orforglipron, the active ingredient in FOUNDAYO tablets. The diagram shows the molecular arrangement including fluorine atoms, various nitrogen-containing rings, and a calcium ion complex.*

FDA Label Image

Figure 1 (Fou Uspi F1 V1)

A line graph showing percentage change in body weight over 72 weeks post randomization for three dosages of FOUNDAYO tablets (5.5 mg, 9 mg, 17.2 mg) compared to placebo. The graph indicates greater weight reduction with increasing dosages of FOUNDAYO compared to minimal change with placebo. The number of patients per group is noted below the graph.*

FDA Label Image

Figure 2 (Fou Uspi F2 V1)

A line graph showing the percentage change in body weight over 72 weeks post-randomization for three dosages of FOUNDAYO tablets (5.5 mg, 9 mg, and 17.2 mg) compared to placebo. The graph depicts greater weight reduction with increasing FOUNDAYO dosages, with placebo showing minimal change. Patient numbers at various time points are noted below the x-axis.*

FDA Label Image

Figure 3 (Fou Uspi F3 V1)

A cumulative frequency chart showing the percentage change in body weight versus cumulative frequency for FOUNDAYO tablets at 5.5 mg, 9 mg, 17.2 mg doses, and placebo. The x-axis represents percent change in body weight from -55% to +35%, and the y-axis shows cumulative frequency from 0% to 100%. Different line styles distinguish each treatment group.*

FDA Label Image

Figure 4 (Fou Uspi F4 V1)

A cumulative frequency graph depicting the change in body weight percentage for FOUNDAYO tablets at strengths of 5.5 mg, 9 mg, and 17.2 mg compared to a placebo. The x-axis represents change in body weight (%) and the y-axis shows cumulative frequency (%). Four curves are plotted for FOUNDAYO 5.5 mg, FOUNDAYO 9 mg, FOUNDAYO 17.2 mg, and placebo.*

FDA Label Image

Foundayo (orforglipron) Tablets 0.8 mg 30 Count Package (Fou 0.8mg Cart 793697)

FDA Label Image

Foundayo (orforglipron) Tablets 2.5 mg 30 Count Package (Fou 2.5mg Cart 793700)

FDA Label Image

Foundayo (orforglipron) Tablets 5.5 mg 30 Count Package (Fou 5.5mg Cart 793706)

FDA Label Image

Foundayo (orforglipron) Tablets 9 mg 30 Count Package (Fou 9mg Cart 793710)

FDA Label Image

Foundayo (orforglipron) Tablets 14.5 mg 30 Count Package (Fou 14.5mg Cart 793715)

FDA Label Image

Foundayo (orforglipron) Tablets 17.2 mg 30 Count Package (Fou 17.2mg Cart 793720)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.